With a market cap of $50.5 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions ...

Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging ...

On Feb. 6, Baird raised Cencora's price target to $307 from $305 while maintaining an “Outperform” rating, citing another strong earnings beat and upward guidance revision. COR’s mean price ...

With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score ... Chesterbrook, PA-based Cencora is one of the world’s largest pharmaceutical ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the execution of a five-year ...

How to Order TRIESENCE TRIESENCE (J-Code 3300) is available to healthcare providers directly through major pharmaceutical wholesale distributors, including Cencora, Cardinal Health, and McKesson.

Cencora, Inc. (NYSE:COR – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports.

In a recent 8-K filing with the Securities and Exchange Commission, Cencora, Inc., a Delaware-based company in the wholesale drug industry and a prominent player in Healthcare Providers & Services ...